JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

NCT06678282 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

B-NHL
B-ALL

Interventions

DRUG: JY231 Injection

Sponsor

Shenzhen Genocury Biotech Co., Ltd.